A review of worldwide clinical trials with norfloxacin in the treatment of uncomplicated urinary tract infections (UTIs), as well as our personal experience with 215 assessable patients, is presented. Almost all patients received 400 mg b.i.d. for 3-15 days. Bacteriological eradication (10(4) CFU/ml of urine or less) was achieved in more than 90% of patients. Short-term therapy (3 days) with norfloxacin proved to be as effective and tolerable as a 10- to 14-day conventional therapeutic schedule in the treatment of lower uncomplicated UTIs. Overall incidence of drug-related adverse experiences was 2.3%.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1159/000464085 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Rhabdomyolysis Following Trimethoprim-Sulfamethoxazole Therapy: A Case Report and Review of the Literature.
Curr Drug Saf
January 2025
National Center Chalbi Belkahia of Pharmacovigilance, Department of Collection and Analysis of Adverse Effects, Tunis, Tunisia, University of Tunis El Manar, Faculty of Medicine, Research unit: UR17ES12, Tunis, Tunisia.
Background: Trimethoprim-Sulfamethoxazole (TMP-SMX) is a commonly used antibiotic for the treatment of several infections, such as urinary tract infections, respiratory infections, and in certain cases, septic arthritis. Rhabdomyolysis (RM) is very rare and less than 20 cases have been reported, so far, in the literature, in particular in immunocompromised patients. Here, we report a case of TMP-SMX-induced RM in an immunocompetent patient, adding to the limited data on this association.
View Article and Find Full Text PDFSodium-Glucose Co-Transporter 2 Inhibitors and Severe Urinary Tract Infections: Real-World Meta-Analysis of Cohort Studies.
Ann Pharmacother
January 2025
Faculty of Medical & Health Sciences, Tel Aviv University, Tel Aviv, Israel.
Objective: There is limited knowledge about severe urinary tract infections associated with SGLT2i, despite this being the basis for the Food and Drug Administration (FDA) warning. We aim to provide real-world evidence to clarify this relationship further.
Data Source: A literature review was performed in PubMed and Embase for cohort studies published up to August 2024 using PICO-consistent terms.
Essential oils modulate virulence phenotypes in a multidrug-resistant pyomelanogenic Pseudomonas aeruginosa clinical isolate.
Sci Rep
January 2025
School of Biotechnology, Amrita Vishwa Vidyapeetham, Amritapuri, Kerala, India.
Pyomelanogenic P. aeruginosa, frequently isolated from patients with urinary tract infections and cystic fibrosis, possesses the ability to withstand oxidative stress, contributing to virulence and resulting in persistent infections. Whole genome sequence analysis of U804, a pyomelanogenic, multidrug-resistant, clinical isolate, demonstrates the mechanism underlying pyomelanin overproduction.
View Article and Find Full Text PDFA study on the effect of blue light on kidney stone formation in rats via the brain-kidney axis.
Sci Rep
January 2025
Department of Urology, Songjiang hospital affiliated to Shanghai jiaotong university school of medicine, Shanghai, China.
Kidney stones, a common urological disease, may involve the brain-kidney axis in their formation, though the specific mechanism remains unclear. This study aimed to investigate the effects of blue light on relevant metabolic indicators and oxidative stress status in rats with kidney stones through the brain-kidney axis. A rat model of kidney stones was established by administering 1% ethylene glycol and 2% ammonium chloride.
View Article and Find Full Text PDFLetter to the editor: "Microbiology and risk factors for bacteremic urinary tract infection: insights from the largest urological center in Pakistan".
Int Urol Nephrol
January 2025
Department of Medicine, Jinnah Sindh Medical University, V22W+F2H, Rafiqui H.J, Iqbal Shaheed Rd, Karachi Cantonment Karachi, Karachi City, 75510, Sindh, Pakistan.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!